<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang A</submitter><funding>NIEHS NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1398</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8674298</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(1)</volume><pubmed_abstract>The human Apolipoprotein E4 (ApoE4) variant is the strongest known genetic risk factor for Alzheimer's disease (AD). Cadmium (Cd) has been shown to impair learning and memory at a greater extent in humanized ApoE4 knock-in (ApoE4-KI) mice as compared to ApoE3 (common allele)-KI mice. Here, we determined how cadmium interacts with ApoE4 gene variants to modify the gut-liver axis. Large intestinal content bacterial 16S rDNA sequencing, serum lipid metabolomics, and hepatic transcriptomics were analyzed in ApoE3- and ApoE4-KI mice orally exposed to vehicle, a low dose, or a high dose of Cd in drinking water. ApoE4-KI males had the most prominent changes in their gut microbiota, as well as a predicted down-regulation of many essential microbial pathways involved in nutrient and energy homeostasis. In the host liver, cadmium-exposed ApoE4-KI males had the most differentially regulated pathways; specifically, there was enrichment in several pathways involved in platelet activation and drug metabolism. In conclusion, Cd exposure profoundly modified the gut-liver axis in the most susceptible mouse strain to neurological damage namely the ApoE4-KI males, evidenced by an increase in microbial AD biomarkers, reduction in energy supply-related pathways in gut and blood, and an increase in hepatic pathways involved in inflammation and xenobiotic biotransformation.</pubmed_abstract><journal>Communications biology</journal><pubmed_title>Cadmium exposure modulates the gut-liver axis in an Alzheimer's disease mouse model.</pubmed_title><pmcid>PMC8674298</pmcid><funding_grant_id>R01 GM111381</funding_grant_id><funding_grant_id>R01 ES030197</funding_grant_id><funding_grant_id>T32 ES015459</funding_grant_id><funding_grant_id>P42 ES004696</funding_grant_id><funding_grant_id>R01 ES026591</funding_grant_id><funding_grant_id>P30 ES007033</funding_grant_id><funding_grant_id>R01 ES025708</funding_grant_id><funding_grant_id>T32 ES007032</funding_grant_id><pubmed_authors>Xia Z</pubmed_authors><pubmed_authors>Gu H</pubmed_authors><pubmed_authors>Matsushita M</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Cui JY</pubmed_authors><pubmed_authors>Zhang A</pubmed_authors><pubmed_authors>Shi X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cadmium exposure modulates the gut-liver axis in an Alzheimer's disease mouse model.</name><description>The human Apolipoprotein E4 (ApoE4) variant is the strongest known genetic risk factor for Alzheimer's disease (AD). Cadmium (Cd) has been shown to impair learning and memory at a greater extent in humanized ApoE4 knock-in (ApoE4-KI) mice as compared to ApoE3 (common allele)-KI mice. Here, we determined how cadmium interacts with ApoE4 gene variants to modify the gut-liver axis. Large intestinal content bacterial 16S rDNA sequencing, serum lipid metabolomics, and hepatic transcriptomics were analyzed in ApoE3- and ApoE4-KI mice orally exposed to vehicle, a low dose, or a high dose of Cd in drinking water. ApoE4-KI males had the most prominent changes in their gut microbiota, as well as a predicted down-regulation of many essential microbial pathways involved in nutrient and energy homeostasis. In the host liver, cadmium-exposed ApoE4-KI males had the most differentially regulated pathways; specifically, there was enrichment in several pathways involved in platelet activation and drug metabolism. In conclusion, Cd exposure profoundly modified the gut-liver axis in the most susceptible mouse strain to neurological damage namely the ApoE4-KI males, evidenced by an increase in microbial AD biomarkers, reduction in energy supply-related pathways in gut and blood, and an increase in hepatic pathways involved in inflammation and xenobiotic biotransformation.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2022-02-11T14:34:40.627Z</modification><creation>2022-02-11T14:34:40.627Z</creation></dates><accession>S-EPMC8674298</accession><cross_references><pubmed>34912029</pubmed><doi>10.1038/s42003-021-02898-1</doi></cross_references></HashMap>